Abstract
In the past few years, three classes of substances have emerged as effective treatments for PAH: prostanoids, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors 2. These substances act by different modes of action. Prostanoids replace endogenous prostacyclin, production of which is decreased or absent in the pulmonary vessels of PAH patients 3, 4, and exert vasodilatory and antiproliferative effects predominantly via the intracellular second messenger, cyclic adenosine 5′-monophosphate (cAMP). Endothelin-1 is overexpressed in PAH and causes deleterious effects such as pulmonary vasoconstriction and vascular smooth muscle cell proliferation 5; effects which are blocked by the administration of endothelin receptor antagonists. Phosphodiesterase-5 inhibitors augment the action of endogenous nitric oxide by inhibiting degradation of the second messenger cyclic guanosine 5′-monophosphate (cGMP) 6, thereby causing pulmonary vasodilatation and inhibition of vascular smooth muscle cell proliferation 7. Thus, since all these substances act via different intracellular pathways, combining them may exert synergistic effects.

This publication has 27 references indexed in Scilit: